European approval for combination lumacaftor/ivacaftor paediatric cystic fibrosis drug
A paediatric treatment for 2 to 5 year olds has been approved by the European Commission to treat children with the most common form of cystic fibrosis...
List view / Grid view
A paediatric treatment for 2 to 5 year olds has been approved by the European Commission to treat children with the most common form of cystic fibrosis...
A blood test could transform the way doctors treat people affected by cystic fibrosis, helping to personalise treatments to individual people...
New research highlights effective methods for identifying a common side effect in children receiving drug treatments for Cystic fibrosis...
Polyphor Ltd has announced €5m funding, in order to support and accelerate the development of an inhaled dosage form of murepavadin...
Researchers have developed a method that could make magnetic resonance imaging (MRI) multicoloured - a strategy that could serve as a research tool and even aid disease diagnosis...
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Laurent Pharmaceuticals has received a Therapeutics Development Award of $3 million from US-based Cystic Fibrosis Foundation Therapeutics...
1 July 2016 | By Caroline Richards, Editor, European Pharmaceutical Review
Here, Caroline Richards, Editor of European Pharmaceutical Review, discusses cystic fibrosis and the treatment options that are currently available or in development...
20 June 2016 | By Victoria White, Digital Content Producer
Verona Pharma has successfully secured funding commitments to raise gross proceeds of £44.7m through a conditional placing with new and existing investors...
17 June 2016 | By Victoria White, Digital Content Producer
NICE has said it will not be able to recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis...
6 June 2016 | By Victoria White, Digital Content Producer
POL6014 is a highly selective, potent and reversible inhibitor of hNE. Increased levels of hNE is associated with cystic fibrosis...
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
23 March 2016 | By Victoria White
Polyphor's POL6014 reduces the activity of elastase, an enzyme that destroys lung tissue when it is produced in excess...
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.